PHI and Malmö University have a long-standing collaboration, dating back to 2008. The collaboration has resulted in several peer reviewed publications and a doctoral thesis. In late 2016, the European Commission granted 2.1 million euro to GlycoImaging – a joint cancer research project to develop improved methods for clinically diagnosing cancer.
Current methods for diagnosing cancer primarily focus on the proteins associated with cancer. However, there is increasing evidence that carbohydrates play an important role in the development and progression of malignant cancer. Current methods use and rely on antibodies created by living organisms. These natural antibodies, however, are not sufficiently specific to accurately detect and image carbohydrates.
The GlycoImaging project is coordinated by Malmö University and commercialized by PHI. Additional partners are Bundesanstalt für Materialforschung und Prüfung (Germany’s federal technology research institute), Umeå, Copenhagen and Turku University.
Popular lecture on cancer research by Prof. Anette Gjörloff Wingren 2016 (in Swedish).
A short presentation of GlycoImaging by Prof. Anette Gjörloff Wingren (in Swedish).
The GlycoImaging video (in Swedish).
Interviews and News
PHI’s Industrial Doctoral Student Louise Stenbaeck received a prize from Danish Cancer Society for her poster “Holographic microscopy: Macrophage-uptake of SA-MIPs”.
“In the near future”, Zahra El-Schich says, “you could have a HoloMonitor in every clinic. You could also customize cancer treatment for every patient by just using a simple tumor test.” Find out how.
Using nanoparticles and HoloMonitor technology Prof. Anette Gjörloff Wingren and her team aim to develop an early screening method that detects cancer by a simple blood test.
GlycoImaging is a collaboration project between PHI, Malmö University and four international research institutions. By combining PHI’s HoloMonitor technology with a new type of cancer probes, more sensitive methods to detect and diagnose cancer at an earlier stage than what is possible today.
EU grants 2.1 million euro to Phase Holographic Imaging and Malmö University with partners for joint cancer research
The European Commission has appointed Phase Holographic Imaging,Bundesanstalt für Material-forschung und Prüfung (Germany’s federal technology research institute), Malmö, Umeå, Copenhagen and Turku University to develop improved methods for clinically diagnosing cancer.
PHI’s HoloMonitor® technology allows cancer researchers to effortlessly monitor the reduction in cancer cell growth in real-time without disturbing or destroying precious patient samples. Unlike cytotoxic cancer drugs, cytostatic drugs do not kill cancer cells. Instead they stop tumor growth by stopping cancer cells from multiplying. As a result cytostatic treatments have fewer side effects than …
Faculty of Health and Society,
Jan Waldenströms gata 25, AS:F502
205 06 Malmö, Sweden